Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593227 · ClinicalTrials.gov registry record · Phase 2
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Marker Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT02593227: Completed Phase 2 study of Breast Cancer, sponsored by Marker Therapeutics.
NCT02593227 is a Phase 2 study of Breast Cancer that has completed, run by Marker Therapeutics. The registered enrollment target is 80 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593227, a Phase 2 study of Breast Cancer, has completed, sponsored by Marker Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Primary Outcome
Emergence of B and T cell immunity targeting the folate receptor alpha
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL Low dose FRα vaccine
- BIOLOGICAL High dose FRα vaccine
Study Locations (11)
New York
- Mount Sinai Hospital - New York
- Montefiore Medical Center, Einstein Cancer Center - New York
Florida
- Moffitt Cancer Center - Tampa
Kansas
- University of Kansas Cancer Center - Westwood
Maryland
- University of Maryland - Greenebaum Cancer Center - Baltimore
Michigan
- Karmanos Cancer Center - Detroit
Missouri
- MidAmerica Division,Inc - Kansas City
New Jersey
- The Valley Hospital - Paramus
Ohio
- Oncology Hematology Care - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-07-15 |
| Phase | Phase 2 |
What the finished NCT02593227 record still lists
NCT02593227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02593227 lists 11 locations in 10 states (New York, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT02593227 about?
NCT02593227 is a clinical study titled "Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer". This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients ...
What is the current status of trial NCT02593227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-04. Estimated completion is 2021-07-15.
What conditions does trial NCT02593227 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02593227?
The interventions under investigation include: Cyclophosphamide (DRUG), Low dose FRα vaccine (BIOLOGICAL), High dose FRα vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593227?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02593227 being conducted?
This trial has 11 study locations across Florida, Kansas, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02593227's enrollment target sits among peer trials
80 649th of 1224 higher than 566 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia